Treats itching of the eye associated with allergic conjunctivitis. ANDA 209620, held by Alembic. Azelastine Hydrochloride.
As of Nov 16, 2026, ANDA 209620 (Azelastine Hydrochloride), held by Alembic, was first approved by FDA on Mar 20, 2019, with 0 approved supplements and 0 published complete response letters.
INDICATIONS & USAGE Azelastine hydrochloride ophthalmic solution 0.05% is indicated for the treatment of itching of the eye associated with allergic conjunctivitis.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 20, 2019 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Azelastine Hydrochloride0.05% · solution/drops;ophthalmic | Azelastine Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters